Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Prototype Ultrasound Bioreactor Assesses Engineers Tissue while Making It

By BiotechDaily International staff writers
Posted on 17 May 2012
Image: Biomedical engineer Jenni Popp with NIST’s prototype bioreactor for tissue engineering. The bioreactor both stimulates and evaluates engineered tissue as it grows (Photo courtesy of Burrus/NIST).
Image: Biomedical engineer Jenni Popp with NIST’s prototype bioreactor for tissue engineering. The bioreactor both stimulates and evaluates engineered tissue as it grows (Photo courtesy of Burrus/NIST).
American scientists have devised a prototype bioreactor--a device for culturing cells to create engineered tissues--that both stimulates and assesses tissue as it grows, simulating natural mechanisms while eliminating the need to stop periodically to snip off samples for analysis. Tissue created in this manner might soon be used to replace, for example, injured or diseased cartilage in the hip and knee.

Conventional techniques for evaluating the development and properties of engineered tissue are time-consuming, destructive and need to be repeated many times. By using ultrasound to monitor tissue during processing without destroying it, the novel bioreactor could be a faster and less expensive alternative.
“Most bioreactors don’t do any type of nondestructive evaluation,” said the US National Institute of Standards and Technology (NIST; Boulder, CO, USA) postdoctoral researcher Jenni Popp, first author of a new article about the instrument, published online April 26, 2012, in the Journal of Medical Devices, and to be published the June 2012 print issue. “Having some sort of ongoing evaluation of the developing tissue is definitely novel.”

Natural cartilage is created by specialized cells that generate large amounts of structural proteins to weave a tough support material called extracellular matrix. Lacking blood vessels, cartilage has limited capability to heal from arthritis, injuries, or other defects. Damage can be treated with drugs or joint replacement but results can be imperfect. Engineered tissue is used in some medical treatments but is not yet a routine option to metal or plastic joint replacements. The NIST bioreactor provides researchers with a noninvasive way to monitor vital structural changes in developing tissue.

The NIST/CU bioreactor can fit inside a standard incubator, which controls temperature and acidity in the growth environment. The bioreactor applies force to stimulate five small cubes of cartilage cells embedded in water-based gels. The mechanical force mimics the natural stimuli needed for the cells to create matrix proteins and develop the structure and properties of real cartilage. Ultrasound techniques monitor tissue changes over time, while a digital video microscope takes images.

Early research indicates the bioreactor both stimulates and monitors development of cells, matrix content, and scaffolds to make three-dimensional (3D) engineered cartilage. The cell-laden gels were stimulated twice daily for an hour. Sulfated glycosaminoglycan (sGAG)--which combines with fibrous proteins to form the extracellular matrix--increased significantly after seven days. This structural change was detected by a significant decrease in ultrasound signals after seven days.
The research described in the article was performed at and led by NIST. The bioreactor is a collaborative project with several investigators from the University of Colorado Boulder (CU; USA) department of chemical and biological engineering.

NIST and CU researchers are continuing to develop ultrasonic measurement methods and plan to conduct longer experiments. The bioreactor is also being used by other academic researchers as a tool for confirming mathematical models of biokinetics, the study of growth and movement in developing tissue.

Related Links:

National Institute of Standards and Technology

University of Colorado Boulder



Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.